GlassScriptPhysician profile
Karina Pena
NPI 1104275502
$4,111.64
in general payments reported to CMS, 2019-2025
28 companies · $586 in 2025
The $586 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $374 · 2022: $564 · 2023: $1,468 · 2024: $1,120 · 2025: $586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,174.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $788.90 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $650.04 | 2021-2025 | |
| Lilly USA, LLC | $477.40 | 2021-2024 | Mounjaro, Trulicity, Emgality |
| Astrazeneca Pharmaceuticals LP | $268.55 | 2021-2025 | Farxiga, Airsupra |
| Pfizer INC. | $263.56 | 2023-2025 | |
| Amgen INC. | $224.93 | 2023-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.12 | 2021-2024 | Jardiance |
| Intuity Medical INC | $170.25 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Abbott Laboratories | $128.04 | 2024-2025 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $112.66 | 2022-2025 | Austedo, Austedo Xr, Ajovy |
| Viiv Healthcare Company | $99.77 | 2023-2024 | Apretude |
| Astellas Pharma US INC | $95.52 | 2023-2025 | Veozah |
| Phathom Pharmaceuticals, INC. | $75.56 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $74.78 | 2022-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $68.96 | 2022-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $66.22 | 2024 | Inspire |
| Ardelyx, INC. | $57.77 | 2024-2025 | Ibsrela |
| Otsuka America Pharmaceutical, INC. | $47.54 | 2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $46.10 | 2021-2023 | Xarelto |
| Biohaven Pharmaceutical Holding Company LTD. | $33.88 | 2022 | |
| Amarin Pharma, INC. | $30.68 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.07 | 2024 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28.00 | 2025 | Caplyta |
| Exact Sciences Corporation | $22.82 | 2023 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $22.65 | 2024 | Gemtesa |
| Allergan, INC. | $18.46 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.90 | 2022 | |
| Phadia US INC. | $14.51 | 2025 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karina Pena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.